Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is among the best fast money stocks to buy now. During the second quarter, Pallas Capital Advisors acquired a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) through the purchase of 13,182 shares of the company’s stock. According to the latest filing with the SEC, the firm’s investment in the company is approximately $59,000.

There are many advocates for Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), and it comes as no surprise. The company has managed to strike another deal with Novartis, which involves both companies developing molecular glue degraders for immune-mediated disorders. This is yet another major highlight as it brings forth $120 million in proceeds, along with the potential to generate $5.7 billion in milestone payments.

Why Core Scientific Inc. (CORZ) Skyrocketed Today

If that weren’t already a strong case, Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been awarded IND clearance from the FDA to accelerate MRT-8102, a second molecular glue degrader. As long as the company executes its initiatives successfully, we have a good reason to believe in the potential for this stock to be rewarding.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is a Massachusetts-based clinical-stage biotechnology company developing novel small-molecule precision medicines. Incepted in 2019, the company maintains a strategic partnership and licensing agreement with F. Hoffmann-La Roche Ltd.

While we acknowledge the potential of GLUE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GLUE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.